Pharma
NewsBY
- MPs have been on the Hill for less than three months this year thanks to prorogation this past winter and the spring election campaign, making lobbying a challenge in 2025.
NewsBY
- MPs have been on the Hill for less than three months this year thanks to prorogation this past winter and the spring election campaign, making lobbying a challenge in 2025.
- As an emergency room doctor, I watch seniors decide between groceries and blood pressure pills; I see new immigrants ration insulin. In a country
- As an emergency room doctor, I watch seniors decide between groceries and blood pressure pills; I see new immigrants ration insulin. In a country
- As an emergency room doctor, I watch seniors decide between groceries and blood pressure pills; I see new immigrants ration insulin. In a country
- The Carney government’s commitment to a national program is in question after the Liberals promised to ‘protect’ pharmacare during the 2025 campaign. Health Minister
- The Carney government’s commitment to a national program is in question after the Liberals promised to ‘protect’ pharmacare during the 2025 campaign. Health Minister
- The Carney government’s commitment to a national program is in question after the Liberals promised to ‘protect’ pharmacare during the 2025 campaign. Health Minister
- Canada must move beyond assuming that a single-payer model alone can solve systemic gaps in access, and design a truly universal system that works
- Canada must move beyond assuming that a single-payer model alone can solve systemic gaps in access, and design a truly universal system that works
- Canada must move beyond assuming that a single-payer model alone can solve systemic gaps in access, and design a truly universal system that works
- Guideline changes became necessary after Justin Trudeau's government chose to amend the Patented Medicines Regulations, a process beset with legal challenges and many delays.
- Guideline changes became necessary after Justin Trudeau's government chose to amend the Patented Medicines Regulations, a process beset with legal challenges and many delays.
- Guideline changes became necessary after Justin Trudeau's government chose to amend the Patented Medicines Regulations, a process beset with legal challenges and many delays.
- Prior to the April 28 federal election, Ottawa secured pharmacare agreements with four jurisdictions: British Columbia, Manitoba, the Yukon, and Prince Edward Island.
- Prior to the April 28 federal election, Ottawa secured pharmacare agreements with four jurisdictions: British Columbia, Manitoba, the Yukon, and Prince Edward Island.
- Prior to the April 28 federal election, Ottawa secured pharmacare agreements with four jurisdictions: British Columbia, Manitoba, the Yukon, and Prince Edward Island.
- The big news in health care these days is national pharmacare. This is surely welcome news for those of us living with any chronic
- The big news in health care these days is national pharmacare. This is surely welcome news for those of us living with any chronic
- The big news in health care these days is national pharmacare. This is surely welcome news for those of us living with any chronic
- Focusing on a list of the most commonly prescribed clinically-important drugs could save billions of dollars, both directly in terms of drug budget, and
- Focusing on a list of the most commonly prescribed clinically-important drugs could save billions of dollars, both directly in terms of drug budget, and
- Focusing on a list of the most commonly prescribed clinically-important drugs could save billions of dollars, both directly in terms of drug budget, and
- Pharmacare is the most innovative and important health policy legislation in decades. To get it right, the federal government must directly engage with patients.
- Pharmacare is the most innovative and important health policy legislation in decades. To get it right, the federal government must directly engage with patients.
- Pharmacare is the most innovative and important health policy legislation in decades. To get it right, the federal government must directly engage with patients.
- Green Party Leader Elizabeth May and NDP Leader Jagmeet Singh have done their part as responsible opposition critics on this policy. Now it’s Pierre
- Green Party Leader Elizabeth May and NDP Leader Jagmeet Singh have done their part as responsible opposition critics on this policy. Now it’s Pierre
- Green Party Leader Elizabeth May and NDP Leader Jagmeet Singh have done their part as responsible opposition critics on this policy. Now it’s Pierre
- Canadians have the chance to consider whether to view access to medicines as a pillar of healthcare, or simply an add-on service.
- Canadians have the chance to consider whether to view access to medicines as a pillar of healthcare, or simply an add-on service.
- Canadians have the chance to consider whether to view access to medicines as a pillar of healthcare, or simply an add-on service.
- Re: “First phase of pharmacare must not ‘create new gaps’ in existing coverage, says lobbyists (The Hill Times, April 1). I strongly endorse the
Opinion | April 8, 2024
Opinion | April 8, 2024
- Re: “First phase of pharmacare must not ‘create new gaps’ in existing coverage, says lobbyists (The Hill Times, April 1). I strongly endorse the
Opinion | April 8, 2024
- Re: “First phase of pharmacare must not ‘create new gaps’ in existing coverage, says lobbyists (The Hill Times, April 1). I strongly endorse the
- Using insulin is always challenging, so access to a broad range of appropriate options is vital.
- Using insulin is always challenging, so access to a broad range of appropriate options is vital.
- Using insulin is always challenging, so access to a broad range of appropriate options is vital.
- Bill C-64 outlines a proposed first phase towards implementation of national universal pharmacare to address accessibility and affordability of prescription drugs and related products.
- Bill C-64 outlines a proposed first phase towards implementation of national universal pharmacare to address accessibility and affordability of prescription drugs and related products.
- Bill C-64 outlines a proposed first phase towards implementation of national universal pharmacare to address accessibility and affordability of prescription drugs and related products.
- The proposed new law would likely prohibit Canadians from purchasing supplemental insurance to cover drugs not covered (or only partially covered) by pharmacare.
- The proposed new law would likely prohibit Canadians from purchasing supplemental insurance to cover drugs not covered (or only partially covered) by pharmacare.
- The proposed new law would likely prohibit Canadians from purchasing supplemental insurance to cover drugs not covered (or only partially covered) by pharmacare.
- The government will likely need to borrow to finance any new spending and add more debt, which will result in higher taxes in the
- The government will likely need to borrow to finance any new spending and add more debt, which will result in higher taxes in the
- The government will likely need to borrow to finance any new spending and add more debt, which will result in higher taxes in the
- Florida’s plan is designed to relieve pressure on an already overburdened government health-care system, and will bring tens, if not hundreds, of millions of
- Florida’s plan is designed to relieve pressure on an already overburdened government health-care system, and will bring tens, if not hundreds, of millions of
- Florida’s plan is designed to relieve pressure on an already overburdened government health-care system, and will bring tens, if not hundreds, of millions of
- The FDA’s Florida decision might wind up limiting Canadians’ access to pharmaceutical medicines as long as Canadian drug prices remain well below prices in
- The FDA’s Florida decision might wind up limiting Canadians’ access to pharmaceutical medicines as long as Canadian drug prices remain well below prices in
- The FDA’s Florida decision might wind up limiting Canadians’ access to pharmaceutical medicines as long as Canadian drug prices remain well below prices in
